Candekern Liều dùng/Hướng dẫn sử dụng

Posology in Hypertension: The recommended initial dose and usual maintenance dose of Candesartan is 8 mg once daily. Most of the antihypertensive effect is attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 16 mg once daily and to a maximum of 32 mg once daily. Therapy should be adjusted according to blood pressure response. Candesartan may also be administered with other antihypertensive agents. Addition of hydrochlorothiazide has been shown to have an additive antihypertensive effect with various doses of Candesartan.
Elderly population: No initial dose adjustment is necessary in elderly patients.
Patients with intravascular volume depletion: An initial dose of 4 mg may be considered in patients at risk for hypotension, such as patients with possible volume depletion (see Precautions).
Patients with renal impairment: The starting dose is 4 mg in patients with renal impairment, including patients on haemodialysis. The dose should be titrated according to response. There is limited experience in patients with very severe or end-stage renal impairment (Cl_creatinine <15 ml/min) (see Precautions).
Patients with hepatic impairment: An initial dose of 4 mg once daily is recommended in patients with mild to moderate hepatic impairment- The dose may be adjusted according to response. Candesartan is contraindicated in patients with severe hepatic impairment and/or cholestasis (see Contraindications, and Pharmacology: Pharmacokinetics under Actions).
Black patients: The antihypertensive effect of candesartan is less pronounced in black patients than in non-black patients. Consequently, uptitration of Candesartan and concomitant therapy may be more frequently needed for blood pressure control in black patients than in non-black patients (see Pharmacology: Pharmacodynamics under Actions).
Posology in Heart Failure: The usual recommended initial dose of Candesartan is 4 mg once daily. Up-titration to the target dose of 32 mg once daily (maximum dose) or the highest tolerated dose is done by doubling the dose at intervals of at least 2 weeks (see Precautions). Evaluation of patients with heart failure should always comprise assessment of renal function including monitoring of serum creatinine and potassium.
Candesartan can be administered with other heart failure treatment, including ACE inhibitors, beta blockers, diuretics and digitalis or a combination of these medicinal products. The combination of an ACE inhibitor, a potassium-sparing diuretic (e.g. spironolactone) and Candesartan is not recommended and should be considered only after careful evaluation of the potential benefits and risks (see Precautions, Adverse Reactions, and Pharmacology: Pharmacodynamics under Actions).
Special patient populations: No initial dose adjustment is necessary for elderly patients or in patients with intravascular volume depletion or renal impairment or mild to moderate hepatic impairment.
Paediatric Population: The safety and efficacy of Candesartan in children aged between birth and 18 years have not been established in the treatment of hypertension and heart failure. No data are available.
Method of administration: Oral use.
Candesartan should be taken once daily with or without food.
The bioavailability of candesartan is not affected by food.